Malmö University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Three-Dimensional Oral Mucosal Equivalents as Models for Transmucosal Drug Permeation Studies
Malmö University, Faculty of Health and Society (HS), Department of Biomedical Science (BMV). Malmö University, Biofilms Research Center for Biointerfaces.
Malmö University, Faculty of Health and Society (HS), Department of Biomedical Science (BMV). Malmö University, Biofilms Research Center for Biointerfaces.
Malmö University, Faculty of Odontology (OD).
Malmö University, Faculty of Health and Society (HS), Department of Biomedical Science (BMV). Malmö University, Biofilms Research Center for Biointerfaces.ORCID iD: 0000-0003-1383-754X
Show others and affiliations
2023 (English)In: Pharmaceutics, E-ISSN 1999-4923, Vol. 15, no 5, p. 1513-1513Article in journal (Refereed) Published
Abstract [en]

Oral transmucosal administration, where drugs are absorbed directly through the non-keratinized, lining mucosa of the mouth, represents a solution to drug delivery with several advantages. Oral mucosal equivalents (OME) developed as 3D in vitro models are of great interest since they express the correct cell differentiation and tissue architecture, simulating the in vivo conditions better than monolayer cultures or animal tissues. The aim of this work was to develop OME to be used as a membrane for drug permeation studies. We developed both full-thickness (i.e., connective plus epithelial tissue) and split-thickness (i.e., only epithelial tissue) OME using non-tumor-derived human keratinocytes OKF6 TERT-2 obtained from the floor of the mouth. All the OME developed here presented similar transepithelial electrical resistance (TEER) values, comparable to the commercial EpiOral™. Using eletriptan hydrobromide as a model drug, we found that the full-thickness OME had similar drug flux to EpiOral™ (28.8 vs. 29.6 µg/cm2/h), suggesting that the model had the same permeation barrier properties. Furthermore, full-thickness OME showed an increase in ceramide content together with a decrease in phospholipids in comparison to the monolayer culture, indicating that lipid differentiation occurred due to the tissue-engineering protocols. The split-thickness mucosal model resulted in 4–5 cell layers with basal cells still undergoing mitosis. The optimum period at the air–liquid interface for this model was twenty-one days; after longer times, signs of apoptosis appeared. Following the 3R principles, we found that the addition of Ca2+, retinoic acid, linoleic acid, epidermal growth factor and bovine pituitary extract was important but not sufficient to fully replace the fetal bovine serum. Finally, the OME models presented here offer a longer shelf-life than the pre-existing models, which paves the way for the further investigation of broader pharmaceutical applications (i.e., long-term drug exposure, effect on the keratinocytes’ differentiation and inflammatory conditions, etc.).

Place, publisher, year, edition, pages
MDPI, 2023. Vol. 15, no 5, p. 1513-1513
Keywords [en]
oral transmucosal delivery, oral mucosal equivalents, drug permeation, 3R principles, 3D in vitro models
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:mau:diva-61046DOI: 10.3390/pharmaceutics15051513ISI: 000997495400001PubMedID: 37242755Scopus ID: 2-s2.0-85160448981OAI: oai:DiVA.org:mau-61046DiVA, id: diva2:1770819
Funder
The Crafoord Foundation, 20210937Knowledge Foundation, 20190010Available from: 2023-06-19 Created: 2023-06-19 Last updated: 2024-07-04Bibliographically approved

Open Access in DiVA

fulltext(3422 kB)310 downloads
File information
File name FULLTEXT01.pdfFile size 3422 kBChecksum SHA-512
79c0e9bfbb17db2c325ea723743884f656482e32bc91f9b46d5647c234bf11b9789998fa8d383bbf50e9649330c724be156303ac346bafb68b978aa8c978d231
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Riaz, AzraGidvall, SannaPrgomet, ZdenkaRuzgas, TautgirdasNilsson, Emelie J.Davies, Julia RValetti, Sabrina

Search in DiVA

By author/editor
Riaz, AzraGidvall, SannaPrgomet, ZdenkaHernandez, Aura RocioRuzgas, TautgirdasNilsson, Emelie J.Davies, Julia RValetti, Sabrina
By organisation
Department of Biomedical Science (BMV)Biofilms Research Center for BiointerfacesFaculty of Odontology (OD)
In the same journal
Pharmaceutics
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 311 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 303 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf